Autolus Therapeutics shares fall 2.50% premarket after European Commission approves CAR-T therapy.

Autolus Therapeutics Plc dropped 2.50% in premarket trading. The decline comes despite the European Commission granting marketing authorization for AUCATZYL (obecabtagene autoleucel), a CAR-T therapy developed by Autolus Therapeutics, to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) in 27 European Union member states. This approval follows prior authorizations from the FDA and the U.K. Medicines and Healthcare products Regulatory Agency.